The Full Wiki

More info on Golimumab

Golimumab: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Golimumab ?
Monoclonal antibody
Type whole antibody
Source human
Target TNFα
CAS number 476181-74-5
ATC code L04AB06
Chemical data
Formula C6530H10068N1752O2026S44 
Mol. mass 147 kDa
Therapeutic considerations
Pregnancy cat.  ?
Legal status -only (US)
Routes Subcutaneous injection

Golimumab (CNTO 148) is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule [1] and hence is a TNF inhibitor.

Golimumab was developed by Centocor and is approved in Canada[2] and the United States[3] as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.[4]

Johnson & Johnson, the parent company of Centocor, requested approval from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.[5] Golimumab will be marketed by Schering-Plough in Europe.[6] Simponi received marketing authorisation from the European Medicines Agency on 1 October 2009.[7]


Large, randomized, double-blind trials in patients with rheumatoid arthritis have shown that golimumab in combination with methotrexate was more effective than methotrexate alone.[8]


Got something to say? Make a comment.
Your name
Your email address